High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes

详细信息    查看全文

• 作者：Maria F. Lopes-Virella^a ; ^{virellam@musc.edu" class="auth_mail" title="E-mail the corresponding author} ; Kelly J. Hunt^b ; Nathaniel L. Baker^b ; Gabriel Virella^c ; The VADT Group of Investigators
• 关键词：Nephropathy ; Albuminuria ; Modified LDL immune complexes ; Modified LDL antibodies ; AGE- LDL ; MDA-LDL
• 刊名：Journal of Diabetes and its Complications
• 出版年：2016
• 出版时间：May-June 2016
• 年：2016
• 卷：30
• 期：4
• 页码：693-699
• 全文大小：434 K

文摘

Circulating immune complexes (IC) containing modified forms of LDL (mLDL) are strongly pro-inflammatory and when present in high levels are associated with the development of diabetic complications.

Objective

We investigated whether levels of oxidized LDL (oxLDL), malondialdehyde-LDL (MDA-LDL) and advanced glycation end products-LDL (AGE-LDL) as well as IgG and IgM antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL isolated from circulating IC were associated with progression to macroalbuminuria in type 2 diabetes (VADT cohort).

Methods

Levels of mLDL in IC were measured in 905 patients, a median of two years after entry into the study. Participants were followed for an average of 3.7 years for renal outcomes. Generalized logistic regression models were used to quantify the association of increased levels of biomarkers and development of abnormal albuminuria. Normal, persistent micro- (ACR ≥ 30), incident micro- (ACR ≥ 30) and incident macroalbuminuria (ACR ≥ 300) were the outcomes of interest.

Results and conclusions

Patients with macro (n = 78) or non-persistent microalbuminuria (n = 81) at baseline were excluded. Odds ratios for endpoints in relation to high versus low (defined using a median split) biomarker levels are found in Fig. 1. Our study demonstrates that high levels of AGE-LDL as well as of IgG antibodies (but not IgM antibodies) reacting with MDA-LDL lysine epitopes in circulating IC predict the development of macroalbuminuria in patients with type 2 diabetes. These data support the pathogenic role of modified LDL IgG antibodies but not the protective role of modified LDL IgM antibodies.